Search Results

with definite sites and domains within SMO and relate them with known cholesterol-binding sequence and structure Structural analysis of SMO domains shows significant changes in the CRD and ICD, during the course of

Here, we present cryoelectron microscopy (cryo-EM) structures of ADGRL3 in complex with Gq, Gs, Gi, and The structures reveal unique ligand-engaging mode, distinctive activation conformation, and key mechanisms The structures also reveal the uncharted structural information of GPCR/G12 coupling.

Here, we report the cryo-electron microscopy structures of GPR110 (ADGRF1), a member of aGPCR, in complex The structures reveal distinctive ligand engaging model and activation conformations of GPR110. The structures also unveil the rarely explored GPCR/G12 and GPCR/G13 engagements.

September 2022 Structure of the human galanin receptor 2 bound to galanin and Gq reveals the basis of To understand the basis of the ligand preferences of the receptors and to assist structure-based drug design, we used cryo-electron microscopy (cryo-EM) to solve the molecular structure of GALR2 bound to Mutant proteins were assayed to help reveal the basis of ligand specificity, and structural comparison

We have combined recently published cryo-electron tomography (cryo-ET) data on the ROS with structural

“There was this very interesting phenotype the lab found where, as a mouse was starting to enter what

HDX-MS-optimized approach to characterize nanobodies as tools for biochemical and structural studies single-chain camelid nanobodies using hydrogen-deuterium exchange (HDX) mass spectrometry (MS) for structural

Here, we discuss recent crystal structures of inactive C5aR1 in terms of an inverted orientation of helix H8, unobserved in other GPCR structures.

While others refined lab techniques, he found himself gravitating toward structural models in his spare He was naturally drawn to analyzing solved protein structures—an activity that, unbeknownst to him, was biology world. At that point, very few GPCR crystal structures had been determined. Collaborating with chemists, biologists, and pharmacologists not only made his predictions more useful

Yet even with the structural biology revolution, one stubborn hurdle persists: prediction.   Can we leverage structural and computational insights not just to explain receptor–ligand interactions His lab sits at the crossroads of structure-based modeling, computational chemistry, and drug discovery GPCR Modeling in Context: Then and Now When Carlsson entered the GPCR field in the early 2000s, structural The next frontier in GPCR drug discovery isn’t more structures—it’s smarter models.

While experimentalists struggled for months with crystallography, he could pull a clean protein structure The GPCR Challenge What makes collaboration non-negotiable in GPCR research is the biology itself. Structural biologists may capture snapshots of receptor conformations, but lack large-scale screening The most effective discovery programs are structured like Carlsson’s: modeling designed with downstream Discover Drugs—People Do In GPCR research, the biggest breakthroughs won’t come from algorithms or crystal structures

August 2022 "Single particle cryogenic-electron microscopy (cryo-EM) is used extensively to determine structures However, applying it to GPCRs without signaling proteins remains challenging because most receptors lack structural Although a similar strategy has the potential to broadly facilitate cryo-EM structure determination of Here, we address this shortcoming by exploring different fusion protein designs, which lead to structures

Recurrent high-impact mutations at cognate structural positions in class A G protein-coupled receptors They have a common structure and, signaling through a much smaller set of G proteins, arrestins, and

October 2022 "We describe production of the human A2A adenosine receptor (A2AAR), a class A G protein-coupled receptor (GPCR) for 19F-NMR and single-molecule fluorescence (SMF) spectroscopy. We explain in detail steps shared between the two sample preparation strategies, including expression and isolation of A2AAR and assembly of A2AAR in lipid nanodiscs and procedures for incorporation of either 19F-NMR or fluorescence probes. Protocols for SMF experiments include sample setup, data acquisition, data processing, and error analysis. For complete details on the use and execution of this protocol, please refer to Wei et al. (2022) and Sušac et al. (2018)." Read more at the source #DrGPCR #GPCR #IndustryNews

small-molecule agonist for a family B GPCR encounters a pattern that recurs often enough to deserve a structural The reason has a structural account. Difficult, for a reason that is structural rather than chemical. It is that allosteric chemistry has a structural advantage when the goal is stabilizing an active state modalities, including peptides themselves, occupy a structural space orthosteric small molecules are

Sandra Berndt talk about new structural perspectives in GPCR-mediated Src family kinase activation.

Allosteric Modulator Discovery: From Serendipity to Structure-Based Design. Structure. 2019;27(4):566-578. 24.         Changeux J-P, Christopoulos A. Nature chemical biology. 2020;16(8):841-849. 44.         Cryo-EM structures of GPCRs coupled to Gs, Gi and Go. Structural insights into G protein activation by D1 dopamine receptor.

Elevate Your GPCR Science with Essential Frameworks for Precision Drug Discovery: An Insight into Advanced Strategies for Targeted Therapeutics. Welcome back GPCR lovers, In pharmacology, the wrong interpretation of antagonist behavior can derail your conclusions, your experiments, and even your program’s credibility. That’s why mastering competitive vs non-competitive antagonism isn’t optional — it’s essential for accurate, defensible science. This week, Terry’s Corner takes you beyond curve shapes into the kinetic and mechanistic realities that separate surface-level analysis from true expertise. Breakthroughs this week: FFA4 receptor signaling controls lipolysis at lipid droplets; novel atypical GPCR-arrestin complexes; Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity. 🔍 This Week in Premium: Sneak Peek A quick look at the curated intelligence our Premium members are using to stay ahead this week: Industry insights:  The latest on how AI is being used to unlock elusive GPCR targets, financial results from Neurocrine Biosciences, and a deep dive into Crinetics Pharmaceuticals’ oral acromegaly drug. We’re also tracking major pipeline clearouts and the competitive landscape for oral GLP-1 drugs. Upcoming events:  An exclusive preview of the “neuroGPCR: G protein coupled receptor signaling in its physiological cellular context” symposium and our featured talk at the upcoming Discovery on Target 2025 conference. Career opportunities:  A curated list of new positions, including a Research Associate, a Senior Research Scientist, and a Post-doctoral Researcher position focused on GPCRs and Mitochondria. Must-read publications:  New insights on RGS protein modulation, GRK2-biased β₂AR signaling, and the distinct role of GRK3 in platelet activation. We’ve also highlighted the latest research on non-canonical internalization mechanisms of mGlu receptors and the intrinsic signaling bias of GPR52. Terry's Corner - Demystifying Antagonism: The Key to Precision Drug Discovery Understanding the nuances of competitive versus non-competitive antagonism is a cornerstone of effective drug discovery. Without a solid grasp of these concepts, scientists risk misinterpreting critical data, leading to flawed decisions and wasted resources. This week in Terry’s Corner , we go beyond the dose-response curves to explore the kinetic and pharmacologic signatures of antagonism. Dr. Kenakin’s expert guidance provides a clear framework for distinguishing these mechanisms and avoiding common pitfalls that can derail a program. Don't let misconceptions about receptor binding kinetics slow your progress—gain the clarity you need to move forward with confidence. Solve the problem of misinterpreting your data by understanding how slow-offset kinetics can mimic classical patterns, leading to incorrect mechanistic assignments. Gain a competitive edge by asking the right questions about binding kinetics and experimental constraints, ensuring your analysis is robust and your decisions are sound. Avoid the professional threat of flawed data interpretations that can lead to costly dead ends and missed opportunities in your drug discovery program. Premium Members get 50%+ discount when they join Terry’s Corner. Sharpen your discovery decisions ➤ Yamina's Consulting Corner - Building Your GPCR Program for Breakthroughs, Not Breakdowns In the fast-paced world of GPCR drug discovery, the "go fast" mindset can often lead to costly breakdowns. Yamina’s Corner tackles the critical disconnect between brilliant science and operational strategy, revealing why throwing more money and people at a problem is a multi-million dollar mistake. This week, we introduce a new series, "The GPCR Precision Blueprint," which provides a systematic framework to ensure your science, strategy, and execution are seamlessly aligned. Learn how to transform your program from a series of disconnected efforts into a predictable, de-risked pathway to success. Solve the problem of a fragmented approach by learning how to build a unified system where every scientific detail and strategic decision aligns. Gain a competitive edge by transforming your GPCR data from chaos into a strategic asset, enabling faster, more confident decision-making. Avoid the professional threat of financial friction and missed investment opportunities by learning to translate operational precision into a compelling narrative for stakeholders. Three takeaways from this week’s feature: Stop firefighting:  Learn why solving isolated problems burns capital without fixing root causes. Bridge science and strategy:  Ensure data and decision-making align with funding and milestones. Build predictable success:  Use a repeatable improvement framework to turn operational chaos into precision execution. Read the full article here ➤ Insights from the Field: The Next Wave of GPCR Drug Discovery The 20th annual GPCR-Based Drug Discovery conference is where the future of GPCR therapies will be defined. If you’re not there, you’re missing out on the next wave of allosteric modulators, biased ligands, and computational targeting. This event is a critical opportunity to stay informed, but the real advantage lies in applying these insights to your work. Our weekly curated news and expert frameworks provide the actionable intelligence you need to make sense of these trends and integrate them into your own research. Solve the problem of information overload by getting a curated summary of the key talks and discussions from the event. Gain a competitive edge by staying on top of the latest breakthroughs in allostery, biased signaling, and computational pharmacology. Avoid the professional threat of falling behind your peers by accessing the same insights that are driving the next generation of drug discovery. Register and join your colleagues in September ➤ Why Dr. GPCR Premium Membership Gives You an Edge In a world filled with noise, Dr. GPCR Premium Membership delivers curated, noise-free intelligence every week. We provide deep-dive expert lessons, classified industry news, priority event alerts, job opportunities, and insider commentary—all designed to help you move faster, smarter, and with greater confidence. This isn’t just information; it’s a strategic framework for your career. Our content is meticulously vetted and organized to provide clarity and actionable insights that you can apply immediately to your work, helping you avoid costly missteps and capitalize on emerging opportunities. FAQ 🔹 What’s included? The complete Weekly News digest, curated jobs, upcoming events, classified GPCR publications, exclusive on-demand expert frameworks, and member-only discounts. 🔹 Who is it for? GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who need fast, curated, career-relevant intelligence to stay ahead. 🔹 Why now? The pace of GPCR innovation is accelerating. Those acting on the right signals today will shape tomorrow’s breakthroughs—and avoid delays others won’t see coming. Don’t Fall Behind—Access the Edge You Need 👉 Become a Premium Member Today ➤ Already a Premium Member? 👉 Access this week’s full Premium Edition here ➤ Hear What Our Members Are Saying “The content had enough depth to satisfy the hunger for theory while being full of practical knowledge.” - DrGPCR University Course Attendee Get a competitive advantage—Join Dr. GPCR Premium Today The breakthroughs are happening now, and the decisions you make today will determine your professional trajectory. Don’t wait for others to lead the way. Join the community of informed, empowered GPCR professionals who are shaping the future of drug discovery. Gain the insights, tools, and connections you need to excel in your field and make your mark. Keywords: GPCR, drug discovery, pharmacology, antagonism, competitive, non-competitive, Terry's Corner, Yamina's Corner, biotech, systems thinking, signal transduction, operational excellence, drug development, pharmaceutical, scientific career Hashtags: #DrGPCR #GPCR #DrugDiscovery #Pharmacology #Biotech #GPCRNews #Science #DrugDevelopment

We hypothesized that there is a common set of receptor interactions made by ligands of diverse structures We computationally docked ~2700 known β2AR ligands to multiple β2AR structures, generating ca 75 000 interpretation of ML analysis in human understandable form allowed us to construct an exquisitely detailed structure‐activity

bioinformatics tools showed that functional mutations in the ADGLR3 gene disrupt the standard and wild ADGRL3 structure

Therefore, it is imperative to understand the precise molecular mechanism of H2R biology.

Watch Episode 171 What happens when your protein has no known ligands, no structure, and very little Enter AlphaFold: Predicting the “Face” of a Receptor When Alessandro began his PhD, structural models —Alessandro Nicoli For the first time, researchers had a reliable set of predicted structures to work Nicoli A New Era of GPCR Research AlphaFold didn’t just fill a gap—it shifted the focus of computational biology More accurate hypotheses, faster ligand discovery, and new strategies to tackle one of biology’s most

For teams building structure–activity relationships (SAR), this insight is gold: you’re not just chasing

GPCR modulators for rare diseases "29/06/2022 Confo Therapeutics, founded in 2015 as a spin-off from VIB and VUB, announced today that it has been awarded a €1.7 million grant from the Flemish Agency for Innovation

However, how these states impact GPCRs biological function and therapeutic targeting remains incompletely

We discuss ligand binding, signaling, and structures of the vGPCRs in light of robust differences from

To better understand the structural basis for this bias, we examined structural models of GPR35 and conducted

previous phase III clinical candidate for the treatment of Crohn's disease, we developed a chemical biology

August 2022 Dopamine D 1 receptor-mediated β-arrestin signaling: Insight from pharmacology, biology,

Given the structural complexity and dynamic nature of GPCRs, generating antibodies that selectively and The collaboration reflects a shared recognition that improving data reproducibility in GPCR biology requires community are both essential for realizing our goal of producing trusted antibody reagents for GPCR biologists Reproducible data are foundational to progress in GPCR biology, target validation, and translational GPCR supports scientists and organizations advancing GPCR biology and GPCR-targeted drug discovery.